William M. Hart, MD, Patricia Doerr, MD, Yuxiao Qian, MD, and Peggy M. McNaull, MD
When errors happen, too often clinicians are at odds with each other about how to respond to a patient or a patient’s loved ones after that patient suffers harm.
AMA J Ethics. 2020;22(4):E298-304. doi:
10.1001/amajethics.2020.298.
Haley Moulton, Benjamin Moulton, JD, MPH, Tim Lahey, MD, MMSc, and Glyn Elwyn, MD, PhD, MSc
Shared decision making in research informed consent conversations is complex due to diverse and potentially divergent interests of investigators and patient-subjects.
AMA J Ethics. 2020;22(5):E365-371. doi:
10.1001/amajethics.2020.365.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Drs Katrina Bramstedt and Ana Iltis discuss the development of QoL assessment tools to help patient-subjects considering reconstructive transplantation.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.